PMID- 21811927
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20110803
IS  - 1976-3786 (Electronic)
IS  - 0253-6269 (Linking)
VI  - 34
IP  - 7
DP  - 2011 Jul
TI  - Inhibitory effects of OD 78 [3-(4-bromo-phenoxy)-4,5-dihydroxybenzoic acid-methyl 
      ester] on the proliferation and migration of TNF-alpha-induced rat aortic smooth 
      muscle cells.
PG  - 1191-9
LID - 10.1007/s12272-011-0718-7 [doi]
AB  - The proliferation and migration of vascular smooth muscle cells (VSMCs) play 
      important roles in the formation and progression of intimal thickening in 
      early-phase atherosclerosis and in restenosis after vascular injury. Tumor 
      necrosis factor-alpha (TNF-alpha) is released from macrophages in atherosclerotic lesions 
      and from neointimal vascular smooth muscle cells after balloon-injury. Obovatol, 
      a major biphenolic component isolated from the Magnolia obovata leaf, is known to 
      have anti-inflammatory and antitumor activities. The goal of this study was to 
      examine the cardioprotective effects of the obovatol derivative OD 78 on the 
      TNF-alpha-induced proliferation and migration of rat aortic smooth muscle cells 
      (RASMCs). The antiproliferative effects of OD 78 on RASMCs were examined by cell 
      counting and [(3)H]-thymidine incorporation assays. Treatment of cells with 1-4 
      muM OD 78 inhibited the proliferation and DNA synthesis of TNF-alpha-stimulated RASMCs 
      in a concentration-dependent manner, without cytotoxicity. Treatment with OD 78 
      inhibited TNF-alpha-mediated p38 phosphorylation, but did not change the activation 
      of extracellular signal-regulated kinase or c-Jun N-terminal kinase. Furthermore, 
      treatment with OD 78 decreased TNF-alpha-induced levels of cyclin E, cyclin D1, CDK2, 
      proliferating cell nuclear antigen, and phosphorylated retinoblastoma protein, 
      but not the CDK4 expression level. Also, OD 78 inhibits the migration of 
      TNF-alpha-induced RASMC in transwells. OD 78 treatment strongly decreased matrix 
      metalloproteinase-9 (MMP-9) expression in a dose-dependent manner, but the MMP-2 
      expression was unchanged. These results show that OD 78 may be developed as a 
      potential antiproliferative agent for the treatment of angioplasty restenosis and 
      atherosclerosis.
FAU - Lim, Yong
AU  - Lim Y
AD  - Department of Clinical Laboratory Science, Dong-eui University, Busan 614-714, 
      Korea.
FAU - Tudev, Munkhtsetseg
AU  - Tudev M
FAU - Park, Eun-Seok
AU  - Park ES
FAU - Kim, Won-Shik
AU  - Kim WS
FAU - Lim, Il-Ho
AU  - Lim IH
FAU - Lee, Mi-Yea
AU  - Lee MY
FAU - Lee, Heesoon
AU  - Lee H
FAU - Jung, Jae-Kyung
AU  - Jung JK
FAU - Hong, Jin-Tae
AU  - Hong JT
FAU - Yoo, Hwan-Soo
AU  - Yoo HS
FAU - Lee, Myung-Koo
AU  - Lee MK
FAU - Pyo, Myoung-Yun
AU  - Pyo MY
FAU - Yun, Yeo-Pyo
AU  - Yun YP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110803
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (3-(4-bromo-phenoxy)-4,5-dihydroxybenzoic acid-methyl ester)
RN  - 0 (Benzoates)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Cyclin E)
RN  - 0 (Phenyl Ethers)
RN  - 0 (Retinoblastoma Protein)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
SB  - IM
MH  - Animals
MH  - Aorta/cytology/drug effects
MH  - Benzoates/metabolism/*pharmacology
MH  - Cardiotonic Agents/metabolism/*pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/*drug effects
MH  - Cyclin E/metabolism
MH  - DNA/analysis/biosynthesis
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Mitogen-Activated Protein Kinase 1/metabolism
MH  - Muscle, Smooth, Vascular/cytology/*drug effects/metabolism
MH  - Myocytes, Smooth Muscle/*drug effects/physiology
MH  - Phenyl Ethers/metabolism/*pharmacology
MH  - Phosphorylation/drug effects
MH  - Rats
MH  - Retinoblastoma Protein/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2011/08/04 06:00
MHDA- 2012/02/01 06:00
CRDT- 2011/08/04 06:00
PHST- 2010/12/08 00:00 [received]
PHST- 2011/03/29 00:00 [accepted]
PHST- 2011/03/21 00:00 [revised]
PHST- 2011/08/04 06:00 [entrez]
PHST- 2011/08/04 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
AID - 10.1007/s12272-011-0718-7 [doi]
PST - ppublish
SO  - Arch Pharm Res. 2011 Jul;34(7):1191-9. doi: 10.1007/s12272-011-0718-7. Epub 2011 
      Aug 3.